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Multidrug resistant pathogens are a widespread problem in the 
hospital setting especially on intensive care units (ICU). This 
study evaluated the susceptibility of clinical isolates of gram-
negative extensively drug resistant organisms (XDR), methicillin-
resistant Staphylococcus aureus (MRSA), and vancomycin-resist-
ant Enterococcus (VRE) to a proprietary chlorhexidine digluco-
nate (CHG) formulation used in one brand of CHG-impregnated 
cloths. Ten isolates each of XDR Pseudomonas aeruginosa, XDR 
Acinetobacter baumannii, XDR Klebsiella pneumoniae, XDR 
Escherichia coli, MRSA, and vancomycin-resistant Enterococcus 
faecium from our hospital were tested. All isolates were suscep-
tible to the proprietary CHG formulation (0.5%, 1%, 2%), with 
99% to 100% suppression of growth at the earliest time point in 
time kill assays (1 minute for gram-positive and 15 seconds for 
gram-negative organisms). Minimum inhibitory concentrations 
ranged from 1 : 4096 to 1 : 65536 for MRSA, 1 : 1024 to 1 : 2048 
for VRE, 1 : 2048 to 1 : 4096 for XDR E. coli, 1 : 512 to 1 : 2048 
for XDR A. baumannii, 1 : 512 to 1 : 1024 for XDR P. aerugi-
nosa, and 1  :  512 to 1  :  1024 for XDR K. pneumoniae. Cloths 
impregnated with this CHG formulation provide effective protec-
tion against colonization and infection by many pathogens. This 
study provides in vitro evidence that the proprietary CHG formu-
lation used in one brand of CHG-impregnated cloths is effective 
against XDR gram-negative organisms, MRSA, and VRE. 
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Summary
Introduction
The rapid emergence and spread of multidrug resistant 
organisms (MDROs) in hospitals is a growing problem 
worldwide [1, 2]. Hospital-acquired infections, particu-
larly those caused by MDROs, are associated with excess 
mortality and morbidity as well as increased hospital 
costs [3-7]. Methicillin-resistant Staphylococcus aureus 
(MRSA), vancomycin-resistant Enterococcus (VRE), 
and multidrug resistant (MDR) gram-negative patho-
gens commonly cause hospital-acquired infections  [8]. 
Managing hospital-acquired infections and MDROs is a 
daily challenge in hospitals, especially from the perspec-
tive of critical care. 
Universal decolonization using topical antiseptic agents 
that reduce the population of microorganisms on patients’ 
skin represents a simple, cost-effective way to prevent 
healthcare-associated infections  [9, 10]. Universal de-
colonization by daily bathing of ICU patients with chlo-
rhexidine digluconate (CHG)-impregnated cloths resulted 
in a substantial reduction in bloodstream infections and 
MRSA acquisition  [9, 11-13]. CHG-impregnated cloths 
have also proven effective in reducing the skin burden of 
MRSA and VRE in ICU patients [9, 14, 15]. 
Evidence suggests that skin colonization with gram-
negative bacterial pathogens may be a root cause of hos-
pital-acquired infections. ICU patients who have diar-
rhea can be particularly at risk of gram-negative bacteria 
dissemination from feces to skin areas on distant parts 
of the body [16]. There is less information concerning 
the utility of CHG on antibiotic-resistant gram-negative 
bacteria [15], although a recent study showed that a pro-
prietary CHG formulation reduced hospital-acquired in-
fections caused by gram-negative bacteria [17]. The ob-
jective of this study was to quantify in vitro the antimi-
crobial effectiveness of a proprietary CHG formulation 
used in one brand of CHG-impregnated cloths against 
gram-negative MDR and extensively drug resistant 
(XDR) clinical isolates (e.g., Pseudomonas aeruginosa, 
Klebsiella pneumoniae, Escherichia coli, Acinetobacter 
baumannii), as well as against clinical isolates of MRSA 
and VRE. 
Materials and methods 
Bacterial Isolates
Clinical isolates of P. aeruginosa, K. pneumoniae, E. 
coli, and A. baumannii selected for testing were classi-
fied as MDR or XDR as described elsewhere [18]. Clini-
cal isolates of MRSA and vancomycin-resistant E. faeci-
um were also tested. Ten consecutive isolates per species 
were collected from patients who were diagnosed with 
an infection cause by a MDRO during their stay in at the 
Heidelberg University Hospital, Germany, in 2014. 
Formulations and Neutralizer
A proprietary 2% CHG formulation (Sage Products 
LLC, Cary, Illinois, US) was tested. The solution used 
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to neutralize the antimicrobial properties of the CHG 
was composed of Caso-bouillon and LTHTh (Heipha, 
Eppelheim, Germany). 
Time Kill Assays
The antimicrobial properties of the proprietary CHG 
formulation at concentrations of 2% (20 mg/ml, the 
original proprietary formulation concentration), 1% 
(10  mg/mL), and 0.5% (5  mg/mL) were determined 
using the quantitative suspension methods described 
by Gebel et al.  [19]. Briefly, bactericidal efficacy 
was determined without organic load. The CHG for-
mulation was diluted in water of standardized hard-
ness. One milliliter of the test organism suspension 
and 1  mL of sterile water of standardized hardness 
were mixed and incubated for 2 minutes, after which 
the test substance was added. The resulting solutions 
were incubated for 1, 3, and 9 minutes, respectively; 
gram-negative organisms were also incubated for 15 
seconds, based on the test procedures outlined in the 
FDA Tentative Final Monograph for Topical Anti-
microbial Drug Products for Over-The-Counter Hu-
man Use (59 FR, 31444, June 17, 1994). At the end 
of the incubation time, 1 mL of the test solution was 
transferred to 10  mL of Caso-bouillon and LTHTh 
and neutralized for 5 minutes. Thereafter, 100 µl and 
500 µl of the neutralized test solution was spread onto 
two agar plates. After incubation for 24 hours at 37 °C 
the colony forming units (CFU) were counted. The 
log 10 reduction was determined as the logarithm to 
the base 10 of the difference between the number of 
cells in the test solution at the beginning of the con-
tact time and at the end.
Determination of the Minimum Inhibitory 
Concentration (MIC)
MIC testing procedures were adapted based on those out-
lined in the FDA Tentative Final Monograph for Topical 
Antimicrobial Drug Products for Over-The-Counter Hu-
man Use (59 FR, 31444, June 17, 1994). Briefly, a 96-well 
microtiter plate (Sarstedt, Nümbrecht, Germany) contain-
ing doubling dilutions of the proprietary CHG in RPMI 
medium (Gibco, Darmstadt, Germany) was set up. CHG 
concentrations started at 2% and were then diluted by 
half. Concentrations for MIC testing were diluted down 
to 1  :  65,536. Wells containing only RPMI were used 
as growth controls. An overnight broth culture of each 
isolate was standardized to 1 x 108 CFU/mL and 50 μL 
volumes of this were added to the microtiter plate. Serial 
dilutions were done and CFUs counted on the plates to 
achieve a concentration of 1 x 105. Plates were incubated 
for 24 hours at 37 °C. The MIC was defined as the low-
est concentration of CHG at which no bacterial growth 
was observed visually on the microtiter plate. Conversion 
of resazurin to resarafin (Sigma-Aldrich, Hamburg, Ger-
many) was used as a visual indicator.
Results
Isolates
Ten isolates each of VRE, MRSA, XDR P. aeruginosa, 
XDR K. pneumoniae, and E. coli were collected and 
tested. Nine isolates of MDR A. baumannii and one of 
XDR A. baumannii were collected and tested.
In Vitro Time Kill Studies
All isolates were highly susceptible to the proprietary 
CHG formulation (Fig. 1). Suppression rates were 99% 
Fig. 1. Time kill at 1 minute with a 2% CHG proprietary solution of clinical isolates of MRSA, vancomycin-resistant E. faecium, and the XDR 
gram-negative pathogens P. aeruginosa, K. pneumoniae, E. coli, and A. baumannii.
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to 100% for all isolates, at all concentrations including 
the lower concentrations of 1% (10 mg/mL) and 0.5% 
(5  mg/mL). The 0.5% CHG formulation provided a 
99.9% reduction of XDR P. aeruginosa, XDR K. pneu-
moniae, XDR E. coli, and XDR and MDR A. baumannii 
from the earliest 15-second time point, and for MRSA 
and VRE at the earliest 1 minute time point. 
MIC Determinations
MICs for the proprietary CHG solution against MRSA 
ranged from 1  : 4096 for a single isolate to 1  : 65536 
(Tab.  I). Nine out of ten XDR E. coli isolates had an 
MIC of 1  : 4096 with the CHG formulations. XDR A. 
baumannii showed relatively low MICs, with an MIC of 
1  :  1024. Vancomycin-resistant E. faecium most com-
monly demonstrated MICs of 1 : 2048. XDR K. pneumo-
nia and XDR P. aeruginosa had slightly higher MICs. 
The MICs for P. aeruginosa MICs ranged from 1 : 512 
to 1 : 1024. MICs for XDR K. pneumoniae ranged from 
1 : 512 to 1 : 4096. 
Discussion
Hospital-acquired infections are leading causes of pre-
ventable morbidity and mortality [2, 20]. Skin decoloni-
zation with CHG-impregnated cloths has been shown to 
reduce the risk of some types of these infections [11, 9, 
12, 13, 16, 21]. This method was shown to be an effec-
tive and cost saving way to reduce the risk of transmis-
sion of MDROs such as MRSA and VRE in the hospital, 
a setting where rapid emergence and spread of MDROs 
is well known [9, 12, 15, 10, 1]. The in vitro time kill 
studies confirmed that all of the German clinical isolates 
tested, including MDR and XDR gram-negative bacte-
ria, MRSA, and vancomycin-resistant E. faecium, were 
highly susceptible to all concentrations of the proprie-
tary CHG formulation used. This was true at the earliest 
time point tested (15 seconds). These results corroborate 
and quantify the effectiveness of the proprietary CHG 
formulation against clinical isolates of MDR and XDR 
gram-negative bacteria in vitro. 
MIC data were more variable than time kill data. We 
observed relatively low MICs for MRSA, E. coli, A. 
baumannii and vancomycin-resistant E. faecium, but 
higher MICs for P. aeruginosa and K. pneumoniae. 
Lack of a consistent relationship between the CHG MIC 
and increased CHG killing has been described previ-
ously with MRSA [22]. The authors noted that the MIC 
did not appear to affect in vitro rate of kill or in vivo 
skin test results, and did not represent CHG resistance. 
The discordance between MIC and kill rate did not af-
fect the utility of CHG decolonization in that study, and 
the same may well be true for the pathogens we stud-
ied. For example, even the MICs we observed against 
P. aeruginosa (e.g., 19.53 µg/mL or 1 : 512) would be 
at least 10-fold lower than the lowest concentrations of 
CHG deposited on skin when the 2% proprietary CHG 
formulation was used  [11]. We conducted our in vitro 
evaluations using the proprietary CHG formulation spe-
cifically because the CHG impregnated cloths have been 
shown to provide consistently high concentrations of an-
tiseptic coverage when applied to skin [11]. 
Conclusions
The present study provides in vitro evidence that the 
proprietary CHG formulation is effective against MDR 
gram-negative organisms, MRSA, and VRE. The solu-
tion we studied is available only in CHG-impregnated 
cloths which are known to provide effective protection 
against colonization and infection by drug resistant path-
ogens. Of course, the 60 clinical isolates tested would not 
be representative of all strains a patient might encounter 
in a German hospital. In addition, higher concentrations 
of the CHG product than were tested in vitro may also be 
more representative of the amount deposited by cloths in 
real-life use. Future research should evaluate the poten-
tial of the cloths to prevent MDROs from colonizing the 
skin and leading to hospital-acquired infections. 
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